Natera | Hosting Partner

Natera is a global leader in cell-free DNA (cfDNA) testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology and organ health. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and reliable tool for early, clinically meaningful rejection assessment. Renasight™ is a comprehensive, accessible renal genetics test for patients with chronic kidney disease. Learn more to help accelerate your research.

medibeacon logo

MediBeacon | Innovation Partner

MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 275 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used. In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing. Data readout of the TGFR Phase 3 Global Pivotal Study is expected in 2022.

NephCure logo LARGE'

NephCure Kidney International | Hosting Partner

NephCure Kidney International’s mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now nearly 30 interventional drug trials for primary glomerular kidney diseases. NephCure is a U.S. tax exempt 501(c)(3) public charity.

For more information, please visit